UK markets closed
NIKKEI 225
27,574.43 -111.97 (-0.40%) HANG SENG
19,450.23 +635.41 (+3.38%) CRUDE OIL
71.69 -0.32 (-0.44%) GOLD FUTURES
1,800.40 +2.40 (+0.13%) DOW
33,751.07 +153.15 (+0.46%) BTC-GBP
14,080.15 +271.09 (+1.96%)
Pfizer Inc. (PFE)
NYSE - Nasdaq Real-time price. Currency in USD
Add to watchlist
As of 03:30PM EST. Market open.
| Previous close | 50.24 |
| Open | 50.18 |
| Bid | 51.59 x 1100 |
| Ask | 51.59 x 800 |
| Day's range | 50.03 - 51.86 |
| 52-week range | 41.45 - 61.71 |
| Volume | |
| Avg. volume | 20,217,530 |
| Market cap | 289.591B |
| Beta (5Y monthly) | 0.65 |
| PE ratio (TTM) | 9.88 |
| EPS (TTM) | 5.22 |
| Earnings date | 06 Feb 2023 - 10 Feb 2023 |
| Forward dividend & yield | 1.60 (3.22%) |
| Ex-dividend date | 03 Nov 2022 |
| 1y target est | 54.78 |
- Zacks
GSK & Others Get Relief as US Court Dismisses Zantac Litigation
A U.S. district court dismisses thousands of lawsuits involving Zantac. Relief for GSK (GSK), Sanofi (SNY) and Pfizer (PFE).
- Zacks
Pfizer (PFE) RSV Vaccine Candidate BLA Gets FDA's Priority Tag
The FDA's decision on Pfizer's (PFE) BLA seeking approval for RSV vaccine candidate in older adults is expected in May 2023.
- Business Wire
Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine in Children Under 5 Years
NEW YORK & MAINZ, Germany, December 08, 2022--Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the U.S. Food and Drug Administration (FDA) granted Emergency Use Authorization (EUA) of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine as the third 3-µg dose in the three-dose primary series for children 6 months through 4 years of age. Children in this age group can receive a primary series consisting of two 3-µg doses of the original Pfizer-BioNTech COVID-19 Vaccine
© 2022 Yahoo. All rights reserved.
